

GW/TMll:gh 4239-64087-01 465306 12/19/05 E-256-1999/0-US-06

RECEIVED  
CENTRAL FAX CENTER

DEC 19 2005

## KLARQUIST SPARKMAN, LLP

16th Floor World Trade Center, 121 S.W. Salmon Street, Portland, Oregon 97204 U.S.A.

PHONE: 503-595-5300 FAX: 503-595-5301

**PLEASE DELIVER DIRECTLY TO EXAMINER LISA V. COOK**

Fax No.: (571) 273-8300

Total No. Pages: 4 including this cover sheet

Message: Transmitted herewith for filing in the below-identified application is a Response to Restriction Requirement. If you do not receive all pages or if you have problems receiving transmittal, please call Gwynedd Warren at (503) 595-5300.

In re application of: *Cuttitta et al.*

Application No. 10/070,853

Filed: August 26, 2002

Confirmation No. 2579

For: DETERMINATION OF ADRENOMEDULLIN-  
BINDING PROTEINS

Examiner: Lisa V. Cook

Art Unit: 1641

Attorney Reference No. 4239-64087-01

## CERTIFICATE OF FACSIMILE

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being facsimile transmitted to the United States Patent and Trademark Office via fax number (571) 273-8300 on the date shown below.

Attorney or Agent  
for Applicant(s)

Tanya M. Harding

Date Transmitted

December 19, 2005

☒ No additional fee is required.☒ Please charge any additional fees that may be required in connection with the filing of this Response to Restriction Requirement, including any necessary application size fees for pages in excess of 100, to Deposit Account 02-4550.  
\_\_\_\_\_  
Tanya M. Harding, Ph.D.  
Registration No. 42,630

December 19, 2005

cc: Docketing

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

GW/TMH:gh 12/19/05 464062.doc E-256-1999/0-US-06  
PATENTAttorney Reference Number 4239-64087-01  
Application Number 10/070,853

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTERIn re application of: *Cuttitta et al.*

Application No. 10/070,853

Filed: August 26, 2002

Confirmation No. 2579

For: DETERMINATION OF  
ADRENOMEDULLIN-BINDING  
PROTEINS

Examiner: Lisa V. Cook

Art Unit: 1641

Attorney Reference No. 4239-64087-01

## CERTIFICATE OF FACSIMILE

DEC 19 2005

I hereby certify that this paper and the documents referred to  
as being attached or enclosed herewith are being facsimile  
transmitted to the United States Patent and Trademark Office  
via fax number (571) 273-8300 on the date shown below.Attorney or Agent  
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Transmitted

December 19, 2005

## RESPONSE TO RESTRICTION REQUIREMENT

This responds to the Office action (Restriction Requirement) dated November 18, 2005, for which a one-month period of reply was set, December 18, 2005 was a Sunday, making a response due on or before Monday, December 19, 2005. This response is timely filed on December 19, 2005. It is believed that no fee is required; however if it is determined that a fee is necessary to file this paper, deposit account authority is provided in the accompanying transmittal letter.

Remarks

Claims 1-52 are pending in this application. Claims 1-52 were subject to a restriction requirement dated November 18, 2005, in which the claims were divided into nine Groups (I-IX). Applicants provisionally elect Group I (drawn to methods of measuring adrenomedullin levels in a sample) with traverse. Applicants request that the requirement for restriction be withdrawn based on the comments provided herein. No amendments are made.

This application is a National Phase of an international patent application filed under the PCT. The applicable standard with respect to restriction practice in a National Phase Application is the Unity of Invention Standard under PCT Rule 13.1 and 13.2. Under PCT Rule 13.2, if various embodiments of an invention are linked by a shared special technical feature it is improper to divide them into separate inventions for the purpose of examination. Accordingly, in the present application, the claims can only be restricted into more than one group for the